4Garcia Rodriguez LA,Duque A,Castellsague J,et al.A cohort study on the risk of acute liver injury among users of keteconazole and other antifungal dross[J].Br J Clin Pharmacol,1999,48(6):847-852.
5Chang CH,Young-Xu Y,Kurth T,et al.The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis:a mete-analysis[J].Am J Med,2007,120 (9):791-798.
7Vickers AE,Sinclair JR,Zollinger M,et al.Mutiple cytochrome P-450s involved in the metabolism of terbinafine snggest a limited potential for drug-drug interactions[J].Drug Metab Dispos,1999,27(9):1029-1038.
8Hall M,Monka C,Krupp P,et al.Safety of oral terbinafine:results of s postmarketing surveillance study in 25,884 patients[J].Arch Dermatol,1997,133(10):1213-1219.
7Gupta AK, Chwetzoff E, Del Rosso J, et al.Hepatic safety of itraconazole. J Cutan Med Surg, 2002, 6: 210-213.
8Gupta AK, Shear NH. Safety review of the oral antifungal agents used to treat superficial mycoses. Int J Dermatol, 1999, 38Suppl 2: 40-52.
9Hall M, Monka C, Krupp P, et al. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol, 1997, 133: 1213-1219.
10Hall AP, Tate B. Acute generalized exanthematous pustulosis associated with oral terbinafine. Australas J Dermatol, 2000, 41:42-45.
